A phase I study (NCT03971409) is currently evaluating anti-C-C chemokine receptor (CCR)8 antibodies, which selectively deplete Tregs in the TME, in combination with immune checkpoint inhibitors for HR+ breast cancer [50]. Here, CCR8 is linked to breast cancer.